{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-091353","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.683143+00:00","generated_at":"2026-06-11T11:29:30.042944+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Outlook Therapeutics reports Q3 net loss $20.7M; reiterates Aug 29 PDUFA for ONS-5010","bullets":["Net loss attributable to common stockholders of $20.7M ($0.08/share) vs $17.5M in prior-year quarter.","Cash and cash equivalents of $33.7M expected to fund operations through potential BLA approval in Q3 2023.","FDA PDUFA goal date of August 29, 2023 for ONS-5010 (ophthalmic bevacizumab) for wet AMD.","Pre-launch activities ongoing with AmerisourceBergen distribution partnership for U.S. launch.","MAA decision from EMA CHMP for ONS-5010 in EU expected in first half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-091353","json":"https://secwatch.observer/filing/0001104659-23-091353.json","markdown":"https://secwatch.observer/filing/0001104659-23-091353.md","text":"https://secwatch.observer/filing/0001104659-23-091353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465923091353/0001104659-23-091353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465923091353/tm2323752d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:29:30.042944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fccaa3f2703b3baa5bbdcc54bd3828f035a742be","claim":"Outlook Therapeutics, Inc. reported financial results for third fiscal quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, Outlook Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for its third fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465923091353/0001104659-23-091353-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third fiscal quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}